NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited
Executive Summary
A completely new form of therapy, the use of viruses to kill cancer cells, is now recommended by NICE for use in melanoma patients in England in final draft guidance, although its future therapeutic and commercial success may depend on positive findings from ongoing combination studies with checkpoint inhibitors and other immunotherapies.
You may also be interested in...
Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.
Discounts Sway NICE As Novartis Outlines Concerns Over New Cancer Drugs Fund
NICE – the HTA body for England and Wales – has recommended that Novartis's Zykadia (ceritinib) be available on the NHS, but only at a discount. Novartis tells Scrip that with the imminent arrival of the UK's new Cancer Drugs Fund (CDF), there are concerns that access to new cancer drugs will become even more difficult.